A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 350
- 试验地点
- 171
- 主要终点
- Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.
研究概览
简要总结
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
详细描述
OncoSignature Selected Cohorts (Arms 1 and 2):
Participants in Arms 1 & 2 will be allocated into two arms based on prospectively predicted sensitivity to ACR-368 using the OncoSignature® Companion Diagnostic test, as follows:
Arm 1: OncoSignature Positive tumors
Arm 2: OncoSignature Negative tumors (completed)
OncoSignature Unselected Cohort (Arm 3 & Arm 4):
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participant must be able to give signed, written informed consent.
- •Participant must have histologically documented, high-grade endometrial cancer.
- •Arms 1 and 2
- •All high-grade epithelial endometrial histological subtypes are eligible including: endometrioid (all Grade 3), serous, carcinosarcomas, clear-cell carcinoma, and mixed histologies.
- •Note: Subjects with p53 mutant Grade 2 endometrioid cancer are eligible
- •Arms 3 and 4
- •Serous carcinoma or mixed tumors with a majority component of serous carcinoma or carcinosarcoma where the carcinomatous component is serous carcinoma.
- •Treatment History Requirements:
- •Arms 1 and 2
- •Subject must have received prior platinum-based chemotherapy
- •Subject must have received prior anti-PD-(L)1 therapy
- •Subject must not have received more than three lines of prior systemic therapy Arms 3 and 4
- •Subject must have received prior platinum-based chemotherapy
- •Subject must have received prior anti-PD-(L)1 therapy
- •Subject must not have received more than two lines of prior systemic therapy
- •Participant must have histologically confirmed metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.
- •Participant must have at least 1 measurable lesion per RECIST v1.1 criteria (by local Investigator) in a baseline tumor imaging that has been obtained within 28 days of the treatment start. Participant must have radiographic evidence of disease progression based on RECIST v1.1 criteria following the most recent line of treatment.
- •Arm 1 and 2 only: Participant must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after written informed consent.
- •Newly obtained is defined as a specimen taken after written informed consent is obtained, during the 28-day Screening period.
- •Note: Subjects at EU sites are not eligible for Arm 1 and Arm 2
- •For all subjects participating in Arm 3 and 4, archival tumor tissue must be provided either during or after screening either as a tissue block or at least 20 unstained slides.
- •Participant must have stabilized or recovered (Grade 1 or baseline) from all prior therapy related toxicities, except as follows:
- •Alopecia is accepted.
- •Endocrine events from prior immunotherapy stabilized at ≤ Grade 2 due to need for replacement therapy are accepted (including hypothyroidism, diabetes mellitus, or adrenal insufficiency).
- •Neuropathy events from prior cytotoxic therapies stabilized at ≤ Grade 2 are accepted.
- •Participant must have an Eastern Cooperative Oncology Group Performance Status 0 or
- •Participant must have an estimated life expectancy of longer than 3 months in the clinical judgment of the investigator.
- •Participant must have adequate organ function at Screening, defined as:
- •Absolute neutrophil count > 1500 cells/µL without growth factor support within 2 weeks prior to obtaining the hematology values at Screening.
- •Hemoglobin ≥ 9.0 g/dL.
- •Platelets ≥ 150,000 cells/µL without transfusion within 1 week prior to obtaining the hematology values at Screening.
- •Renal function is defined as Glomerular filtration rate (GFR) ≥ 50 mL/min/1.73m
- •Note: GFR may be estimated using site standard methods (e.g., CKD-EPI, MDRD, or Cockcroft-Gault) or measured using 24-hour urine collection or Chrome-EDTA clearance, as per site standard practice.
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); ≤ 5 × ULN if liver metastases are present.
- •Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable.
- •Serum albumin ≥ 3 g/dL.
- •Participant must have adequate coagulation profile as defined below if not on anticoagulation. If subject is receiving anticoagulation therapy, then subject must be on a stable dose of anticoagulation for ≥ 1 month:
- •Prothrombin time within 1.5 x ULN.
- •Activated partial thromboplastin time within 1.5 x ULN.
排除标准
- •Participant with known symptomatic brain metastases requiring > 10 mg/day of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.
- •Participant has mesenchymal tumors of the uterus.
- •Participant has a history of clinically meaningful ascites, defined as history of paracentesis or thoracentesis with therapeutic intent, within 4 weeks of Screening. Subjects with planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing are excluded.
- •Participant had systemic therapy or radiation therapy within 3 weeks prior to the first dose of study drug.
- •Participants has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix
- •Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.
- •Participant has cardiovascular disease, defined as:
- •Uncontrolled hypertension defined as blood pressure > 160/90 mmHg at Screening confirmed by repeat (medication permitted).
- •History of torsades de pointes, significant Screening electrocardiogram (ECG) abnormalities, including ventricular rhythm disturbances, unstable cardiac arrhythmia requiring medication, pathologic symptomatic bradycardia, left bundle branch block, second degree atrioventricular (AV) block type II, third degree AV block, Grade ≥ 2 bradycardia, uncorrected hypokalemia not amenable to correction, congenital long QT syndrome, prolonged QT interval due to medications, corrected QT based on Fridericia's formula (QTcF) > 450 msec (for men) or > 470 msec (for women).
- •Symptomatic heart failure (per New York Heart Association guidelines; (Caraballo, 2019), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction < 20%, transient ischemic attack, or cerebrovascular accident within 6 months of Day 1).
- •Participant has a history of major surgery within 4 weeks of Screening.
- •Participant has experienced bowel obstruction related to the current cancer within the last 4 weeks or signs or symptoms of intestinal obstruction, which include nausea, vomiting, or objective radiologic finding of bowel obstruction in the last 4 weeks before the start of the treatment.
- •Participant has taken a prior cell cycle CHK1 inhibitor, including ACR-368
研究组 & 干预措施
OncoSignature Positive Tumors
ARM 1: Participants with OncoSignature Positive Tumors will enter a Phase 2 Simon 2-Stage Study that will assess the efficacy of ACR-368 as monotherapy.
干预措施: OncoSignature (Diagnostic Test)
OncoSignature Positive Tumors
ARM 1: Participants with OncoSignature Positive Tumors will enter a Phase 2 Simon 2-Stage Study that will assess the efficacy of ACR-368 as monotherapy.
干预措施: ACR-368 (Drug)
OncoSignature Negative Tumors
Arm 2: Participants with OncoSignature Negative Tumors will receive ACR-368 with ULDG sensitization. The Phase 2 Study will assess the efficacy and safety of ACR-368 with ULDG sensitization.
干预措施: ACR-368 (Drug)
OncoSignature Negative Tumors
Arm 2: Participants with OncoSignature Negative Tumors will receive ACR-368 with ULDG sensitization. The Phase 2 Study will assess the efficacy and safety of ACR-368 with ULDG sensitization.
干预措施: OncoSignature (Diagnostic Test)
OncoSignature Negative Tumors
Arm 2: Participants with OncoSignature Negative Tumors will receive ACR-368 with ULDG sensitization. The Phase 2 Study will assess the efficacy and safety of ACR-368 with ULDG sensitization.
干预措施: Gemcitabine (Drug)
OncoSignature Unselected (Serous All-Comers) ACR-368 with ULDG
Arm 3: Participants who are OncoSignature Unselected will receive ACR-368 with ULDG sensitization. The Phase 2 Study will assess the efficacy and safety of ACR-368 with ULDG sensitization.
干预措施: Gemcitabine (Drug)
OncoSignature Unselected (Serous All-Comers) ACR-368 with ULDG
Arm 3: Participants who are OncoSignature Unselected will receive ACR-368 with ULDG sensitization. The Phase 2 Study will assess the efficacy and safety of ACR-368 with ULDG sensitization.
干预措施: ACR-368 (Drug)
OncoSignature Unselected (Serous All-Comers) ACR-368
Arm 4: Participants who are OncoSignature Unselected will receive ACR-368. The Phase 2 Study will assess the efficacy and safety of ACR-368.
干预措施: ACR-368 (Drug)
结局指标
主要结局
Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.
时间窗: Response will be assessed every 8 weeks from baseline through 2 years or death.
Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.
Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.
时间窗: Response will be assessed every 8 weeks from baseline through 2 years or death.
Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.
Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).
时间窗: Response will be assessed every 8 weeks from baseline through 2 years or death.
Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.
Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.
时间窗: Response will be assessed every 8 weeks from baseline through 2 years or death.
Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.
Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.
时间窗: Response will be assessed every 8 weeks from baseline through 2 years or death.
Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.
Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).
时间窗: Response will be assessed every 8 weeks from baseline through 2 years or death.
Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.
Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).
时间窗: Response will be assessed every 8 weeks from baseline through 2 years or death.
Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic
次要结局
- Arm 1: Adverse Events (AEs) for ACR-368(AEs will be assessed from baseline through 2 years or death.)
- Arm 2 and Arm 3: Adverse Events (AEs) for ACR-368 with ULDG sensitization(AEs will be assessed from baseline through 2 years or death.)
- All Arms: Limited pharmacokinetic (PK) testing.(Dose of ACR-368 at day 1 and day 15 of first cycle.)
- Overall Survival (OS)(Up to 2 years)
- Duration of Response (DOR)(Up to 2 years)
- Progression-free Survival (PFS)(Up to 2 years)
- Overall Survival (OS)(Up to 2 years)
- Duration of Response (DOR)(Up to 2 years)
- Progression-free Survival (PFS)(Up to 2 years)
- Arm 1 and Arm 4: Adverse Events (AEs) for ACR-368(AEs will be assessed from baseline through 2 years or death.)